Aclaris Reports Positive Phase 1b ATI-052 Results in Dermatitis and Asthma
Aclaris Therapeutics said primary analysis results from a Phase 1b proof-of-concept study of ATI-052 were positive. The company reported rapid and durable skin and itch improvement in a severe atopic dermatitis population.
Story updates
10:04:12 AM UTC
SquawkNews
Aclaris reported positive Phase 1b proof—of—concept results for bispecific ATI-052 in atopic dermatitis and asthma with favorable safety and no conjunctivitis, and plans to prioritize a Phase 2b in eosinophilic esophagitis.Material DetailsContext by AI AnalystThis is early clinical validation of Ac…